Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Frequently asked questions
What sector does Cognition Therapeutics Inc (CGTX) operate in?
Cognition Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Cognition Therapeutics Inc (CGTX) current stock price?
As of the latest data, Cognition Therapeutics Inc stock price is $1.02, with a previous close of $1.01. Cognition Therapeutics Inc gained $0.01 in the last trading session, representing a 0.5% increase.
What is Cognition Therapeutics Inc (CGTX) current market capitalization?
Cognition Therapeutics Inc market cap is approximately 90.84 million.
What is Cognition Therapeutics Inc (CGTX) Earnings Per Share (EPS)?
The trailing EPS is -$0.22, and the forward EPS is -$0.24.
What is Cognition Therapeutics Inc (CGTX) EBITDA?
Cognition Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -7.74 million.
Does Cognition Therapeutics Inc (CGTX) pay dividends?
No. Cognition Therapeutics Inc does not pay a dividend.
What is Cognition Therapeutics Inc (CGTX) beta (volatility) score?
Cognition Therapeutics Inc has a beta of 1.776, suggesting it is more volatile than the market.
